Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
Resistance to antiretroviral drugs is generally conferred by specific amino acid substitutions, rather than insertions or deletions, in reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1). The exception to these findings is the amino acid insertions found in the beta3-beta4 loop of the RT enzyme in response to treatment with nucleoside reverse transcriptase inhibitors. This insert consists most commonly of two amino acids, but we describe in detail the evolution of a variant with an 8-amino-acid (aa) insert in a patient treated with zidovudine (ZDV) and 2'-3'-dideoxycytidine (ddC). The 24-nucleotide insert is a partial duplication of local sequences but also contains a sequence segment of unknown origin. Extensive sequence analysis of longitudinal patient samples indicated that the HIV-1 population prior to the start of therapy contained not the wild-type amino acid 215T in RT but a mixture with 215D and 215C. Treatment with ZDV and subsequent ZDV-ddC combination therapy resulted in the evolution of an HIV-1 variant with a typical ZDV resistance genotype (41L, 44D, 67N, 69D, 210W, 215Y), which was slowly replaced by the insert-containing variant (41L, 44D, insert at position 69, 70R, 210W, 215Y). The latter variant demonstrated increased resistance to a wide range of drugs, indicating that the 8-aa insert augments nucleoside analogue resistance. The gain in drug resistance of the insert variant came at the expense of a reduction in replication capacity when assayed in the absence of drugs. We compared these data with the resistance and replication properties of 133 insert-containing sequences of different individuals present in the ViroLogic database and found that the size and actual sequence of the insert at position 69 influence the level of resistance to nucleoside analogues.
van der Hoek
Lia
L
Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
Back
Nicole
N
Jebbink
Maarten F
MF
de Ronde
Anthony
A
Bakker
Margreet
M
Jurriaans
Suzanne
S
Reiss
Peter
P
Parkin
Neil
N
Berkhout
Ben
B
D000328:Adult; D019943:Amino Acid Substitution; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024921:Drug Resistance, Multiple, Viral / Q000235:genetics*; D019143:Evolution, Molecular; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D054303:HIV Reverse Transcriptase / Q000737:chemistry / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics*; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D009154:Mutation; D011995:Recombination, Genetic; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D017422:Sequence Analysis, DNA; D014779:Virus Replication; D016047:Zalcitabine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D015215:Zidovudine / Q000494:pharmacology / Q000627:therapeutic use
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D016047:Zalcitabine; C050624:2',3'-dideoxycytidinene; D054303:HIV Reverse Transcriptase
Antimicrob Agents Chemother. 2000 Apr;44(4):920-8
10722492
Virology. 2000 May 10;270(2):310-6
10792990
J Virol. 2000 Jul;74(14):6262-8
10864635
Antimicrob Agents Chemother. 2000 Aug;44(8):2109-17
10898683
J Virol. 2000 Sep;74(18):8390-401
10954539
J Virol. 2000 Sep;74(18):8524-31
10954553
EMBO J. 2000 Nov 1;19(21):5752-61
11060026
J Virol. 2001 Jan;75(2):589-94
11134271
J Virol. 2001 Jan;75(2):595-602
11134272
Science. 2001 Apr 6;292(5514):7
11292864
Antimicrob Agents Chemother. 2001 Jun;45(6):1836-42
11353634
J Virol. 2001 Jun;75(12):5604-13
11356968
J Virol. 2001 Aug;75(15):7202-5
11435603
Virology. 2001 Jul 5;285(2):193-203
11437654
J Virol. 2001 Oct;75(20):9644-53
11559796
Intervirology. 2001;44(6):339-43
11805439
J Biol Chem. 2002 Feb 22;277(8):5952-61
11741936
AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):733-6
12167282
J Virol. 2002 Sep;76(18):9143-51
12186898
J Virol. 2002 Oct;76(20):10546-52
12239335
J Virol. 2002 Nov;76(21):11104-12
12368352
J Mol Biol. 2002 Oct 18;323(2):181-97
12381314
J Virol. 2003 Mar;77(6):3871-7
12610164
J Virol. 2003 Apr;77(8):5037-8
12663814
AIDS. 2004 Jul 23;18(11):1571-7
15238775
J Clin Microbiol. 1990 Mar;28(3):495-503
1691208
J Infect Dis. 1992 Jan;165(1):105-10
1370174
Virology. 1992 Dec;191(2):968-72
1448931
Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2398-402
7534421
J Infect Dis. 1995 Jun;171(6):1411-9
7539472
J Infect Dis. 1995 Jul;172(1):70-8
7541064
Antimicrob Agents Chemother. 1999 Aug;43(8):1961-7
10428920
J Virol. 1996 Feb;70(2):1086-90
8551567
Science. 1996 Mar 15;271(5255):1582-6
8599114
J Virol. 1996 Apr;70(4):2146-53
8642636
EMBO J. 1996 Aug 1;15(15):4040-9
8670908
J Virol. 1996 Aug;70(8):5662-4
8764084
Antiviral Res. 1996 Jun;31(1-2):45-57
8793008
J Virol. 1997 Apr;71(4):3346-50
9060708
J Virol. 1997 Jun;71(6):4479-84
9151839
J Virol. 1997 Sep;71(9):6662-70
9261388
J Virol. 1998 May;72(5):3773-8
9557659
J Clin Invest. 1998 Nov 15;102(10):1769-75
9819361
AIDS. 1999 Jan 14;13(1):75-80
10207547
J Hum Virol. 1999 May-Jun;2(3):146-53
10413366